Natural killer cells preferentially target cancer stem cells; role of monocytes in protection against NK cell mediated lysis of cancer stem cells

Current Drug Delivery

Volumn 9, Issue 1, 2012, Pages 5-16

  Jewett, Anahid ^a   Tseng, Han Ching ^a   Arasteh, Aida ^a   Saadat, Saba ^a   Christensen, Russell E ^a   Cacalano, Nicholas A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Cancer stem cells; Differentiation; IL 6; Immunosuppression; NF B; NK; Split anergy

Indexed keywords

CHEMOKINE; CYCLOOXYGENASE 2; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PROSTAGLANDIN E2; SULINDAC; TRANSCRIPTION FACTOR;

ALLOGENEIC NATURAL KILLER CELL TRANSPLANTATION; ALLOTRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CANCER STEM CELL; CELL CONTACT; CELL DIFFERENTIATION; CELL FUNCTION; CLONAL ANERGY; CYTOTOXICITY; EMBRYONIC STEM CELL; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; MESENCHYMAL STEM CELL; MOLECULAR MECHANICS; MONOCYTE; MOUTH TUMOR; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE REGENERATION; TOOTH PULP; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR RESISTANCE;

EID: 83455218183     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720112798375989     Document Type: Review

References (114)

1. Keogh, P.V., Fisher, V., Flint, S.R. Resolution of oral non- Hodgkin's lymphoma by reduction of immunosuppressive therapy in a renal allograft recipient: a case report and review of the literature. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod., 2002, 94, 697-701.
2. Hernandez, G., Arriba, L., Jimenez, C., Bagan, J.V., Rivera, B., Lucas, M., Moreno, E. Rapid progression from oral leukoplakia to carcinoma in an immunosuppressed liver transplant recipient. Oral. Oncol., 2003, 39, 87-90.
3. Bilinska-Pietraszek, E., Namyslowski, G., Mrowka-Kata, K., Scierski, W., Aniol-Borkowska, M. [A case of tongue neoplasm in a 15-year old patient treated with immunosuppressants for renal insufficiency]. Otolaryngol. Pol., 2001, 55, 95-97.
4. de Visscher, J.G., Bouwes Bavinck, J.N., van der Waal, I. Squamous cell carcinoma of the lower lip in renal-transplant recipients. Report of six cases. Int. J. Oral. Maxillofac. Surg, 1997, 26, 120-123.
5. King, G.N., Healy, C.M., Glover, M.T., Kwan, J.T., Williams, D.M., Leigh, I.M., Worthington, H.V., Thornhill, M.H. Increased prevalence of dysplastic and malignant lip lesions in renaltransplant recipients. N. Engl. J. Med., 1995, 332, 1052-1057.
6. van Zuuren, E.J., de Visscher, J.G., Bouwes Bavinck, J.N. Carcinoma of the lip in kidney transplant recipients. J. Am. Acad. Dermatol., 1998, 38, 497-499.
7. Bhatia, S., Louie, A.D., Bhatia, R., O'Donnell, M.R., Fung, H., Kashyap, A., Krishnan, A., Molina, A., Nademanee, A., Niland, J.C., Parker, P.A., Snyder, D.S., Spielberger, R., Stein, A., Forman, S.J. Solid cancers after bone marrow transplantation. J. Clin. Oncol., 2001, 19, 464-471.
8. Goedert, J.J., Cote, T.R., Virgo, P., Scoppa, S.M., Kingma, D.W., Gail, M.H., Jaffe, E.S., Biggar, R.J. Spectrum of AIDS-associated malignant disorders. Lancet, 1998, 351, 1833-1839.
9. Bennett, M.W., O'Connell, J., O'Sullivan, G.C., Brady, C., Roche, D., Collins, J.K., Shanahan, F. (Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol., 1998, 160, 5669-5675.
10. Camp, B.J., Dyhrman, S.T., Memoli, V.A., Mott, L.A., Barth, R.J., Jr. In situ cytokine production by breast cancer tumor-infiltrating lymphocytes. Ann. Surg. Oncol., 1996, 3, 176-184.
11. Gimmi, C.D., Morrison, B.W., Mainprice, B.A., Gribben, J.G., Boussiotis, V.A., Freeman, G.J., Park, S.Y., Watanabe, M., Gong, J., Hayes, D.F., Kufe, D.W., Nadler, L.M. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat. Med., 1996, 2, 1367-1370.
12. Jewett, A., Head, C., Cacalano, N.A. Emerging mechanisms of immunosuppression in oral cancers. J. Dent. Res., 2006, 85, 1061-1073.
13. Kolenko, V., Wang, Q., Riedy, M.C., O'Shea, J., Ritz, J., Cathcart, M.K., Rayman, P., Tubbs, R., Edinger, M., Novick, A., Bukowski, R., Finke, J.Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. J. Immunol., 1997, 159, 3057-3067.
14. Mulder, W.M., Bloemena, E., Stukart, M.J., Kummer, J.A., Wagstaff, J., Scheper, R.J. T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut, 1997, 40, 113-119.
15. Han, X., Papadopoulos, A.J., Ruparelia, V., Devaja, O., Raju, K.S. Tumor lymphocytes in patients with advanced ovarian cancer: changes during in vitro culture and implications for immunotherapy. Gynecol. Oncol., 1997, 65, 391-398.
16. Miescher, S., Stoeck, M., Qiao, L., Barras, C., Barrelet, L., von Fliedner, V. Preferential clonogenic deficit of CD8-positive Tlymphocytes infiltrating human solid tumors. Cancer Res., 1988, 48, 6992-6998.
17. Qin, J., Han, B., Pang, J. [The relationship between TIL from human primary hepatic carcinoma and prognosis]. Zhonghua Yi Xue Za Zhi, 1997, 77, 167-170.
18. Tanaka, H., Nakao, M., Shichijo, S., Itoh, K. Nonsteroidal antiinflammatory drugs differentially regulate cytokine production in human lymphocytes: up-regulation of TNF, IFN-gamma and IL-2, in contrast to down-regulation of IL-6 production. Cytokine, 1995, 7, 372-379.
19. Aggarwal, S., Pittenger, M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 2005, 105, 1815-1822.
20. Selmani, Z., Naji, A., Zidi, I., Favier, B., Gaiffe, E., Obert, L., Borg, C., Saas, P., Tiberghien, P., Rouas-Freiss, N., Carosella, E.D., Deschaseaux, F. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells, 2008, 26, 212-222.
21. Spaggiari, G.M., Capobianco, A., Abdelrazik, H., Becchetti, F., Mingari, M.C., Moretta, L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood, 2008, 111, 1327-1333.
22. Jewett, A., Bonavida, B. Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. J. Immunol., 1996, 156, 907-915.
23. Nakagomi, H., Petersson, M., Magnusson, I., Juhlin, C., Matsuda, M., Mellstedt, H., Taupin, J.L., Vivier, E., Anderson, P., Kiessling, R. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res., 1993, 53, 5610-5612.
24. Rayet, B., Gelinas, C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene, 1999, 18, 6938-6947.
25. Teruel, A., Romero, M., Cacalano, N.A., Head, C., Jewett, A. Potential contribution of naive immune effectors to oral tumor resistance: role in synergistic induction of VEGF, IL-6, and IL-8 secretion. Cancer Immunol. Immunother., 2008, 57 (3), 359-366.
26. Tseng, H.C., Arasteh, A., Paranjpe, A., Teruel, A., Yang, W., Behel, A., Alva, J.A., Walter, G., Head, C., Ishikawa, T.O., Herschman, H.R., Cacalano, N., Pyle, A.D., Park, N.H., Jewett, A. Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS ONE 2010, 5, e11590.
27. Rioux, S., Begin, C., Dubreuil, J.D., Jacques, M. Isolation and characterization of LPS mutants of Actinobacillus pleuropneumoniae serotype 1. Curr. Microbiol., 1997, 35, 139-144.
28. Opitz, O.G., Harada, H., Suliman, Y., Rhoades, B., Sharpless, N.E., Kent, R., Kopelovich, L., Nakagawa, H., Rustgi, A.K. A mouse model of human oral-esophageal cancer. J. Clin. Invest., 2002, 110, 761-769.
29. Jewett, A., Cacalano, N.A., Teruel, A., Romero, M., Rashedi, M., Wang, M., Nakamura, H. Inhibition of nuclear factor kappa B (NFkappaB) activity in oral tumor cells prevents depletion of NK cells and increases their functional activation. Cancer Immunol. Immunother., 2006, 55, 1052-1063.
30. Jewett, A., Wang, M.Y., Teruel, A., Poupak, Z., Bostanian, Z., Park, N.H. Cytokine dependent inverse regulation of CD54 (ICAM1) and major histocompatibility complex class I antigens by nuclear factor kappaB in HEp2 tumor cell line: effect on the function of natural killer cells. Hum. Immunol., 2003, 64, 505-520.
31. Pasparakis, M., Courtois, G., Hafner, M., Schmidt-Supprian, M., Nenci, A., Toksoy, A., Krampert, M., Goebeler, M., Gillitzer, R., Israel, A., Krieg, T., Rajewsky, K., Haase, I. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature, 2002, 417, 861-866.
32. Karin, M., Cao, Y., Greten, F.R., Li, Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer, 2002, 2, 301-310.
33. Burnet, F.M. The concept of immunological surveillance. Prog. Exp. Tumor Res., 1970, 13, 1-27.
34. Burnet, F.M. Immunological surveillance in neoplasia. Transplant. Rev., 1971, 7, 3-25.
35. Burnet, F.M. Implications of immunological surveillance for cancer therapy. Isr. J. Med. Sci, 1971, 7, 9-16.
36. Stutman, O. Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. J. Natl. Cancer Inst., 1979, 62, 353-358.
37. Stutman, O. Spontaneous tumors in nude mice: effect of the viable yellow gene. Exp. Cell Biol., 1979, 47, 129-135.
38. Aggarwal, B.B. Nuclear factor-kappaB: the enemy within. Cancer Cell, 2004, 6, 203-208.
39. Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., Schreiber, R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol., 2002, 3, 991-998.
40. Dunn, G.P., Old, L.J., Schreiber, R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 2004, 21, 137-148.
41. Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J., Schreiber, R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 2001, 410, 1107-1111.
42. Jewett, A., Cavalcanti, M., Bonavida, B. Pivotal role of endogenous TNF-alpha in the induction of functional inactivation and apoptosis in NK cells. J. Immunol., 1997, 159, 4815-4822.
43. Jewett, A., Gan, X.H., Lebow, L.T., Bonavida, B. Differential secretion of TNF-alpha and IFN-gamma by human peripheralblood-derived NK subsets and association with functional maturation. J. Clin. Immunol., 1996, 16, 46-54.
44. Laad, A., Kode, J., Chavan, S., Rao, R., Fakih, A.R., Chiplunkar, S. Limiting dilution analysis of proliferating and cytotoxic lymphocytes in the peripheral blood and tumours of oral cancer patients. Eur. J. Cancer B Oral Oncol., 1996, 32B, 337-342.
45. Trinchieri, G. Biology of natural killer cells. Adv. Immunol., 1989, 47, 187-376.
46. Thomas, D.W., Matthews, J.B., Patel, V., Game, S.M., Prime, S.S. Inflammatory cell infiltrate associated with primary and transplanted tumours in an inbred model of oral carcinogenesis. J. Oral Pathol. Med., 1995, 24, 23-31.
47. Schantz, S.P., Shillitoe, E.J., Brown, B., Campbell, B. Natural killer cell activity and head and neck cancer: a clinical assessment. J. Natl. Cancer Inst., 1986, 77, 869-875.
48. Hoffmann, T.K., Donnenberg, A.D., Finkelstein, S.D., Donnenberg, V.S., Friebe-Hoffmann, U., Myers, E.N., Appella, E., DeLeo, A.B., Whiteside, T.L. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res., 2002, 62, 3521-3529.
49. Cortesina, G., De Stefani, A., Giovarelli, M., Barioglio, M.G., Cavallo, G.P., Jemma, C., Forni, G. Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer, 1988, 62, 2482-2485.
50. Rivoltini, L., Gambacorti-Passerini, C., Squadrelli-Saraceno, M., Grosso, M.I., Cantu, G., Molinari, R., Orazi, A., Parmiani, G. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. Cancer Res., 1990, 50, 5551-5557.
51. Whiteside, T.L., Letessier, E., Hirabayashi, H., Vitolo, D., Bryant, J., Barnes, L., Snyderman, C., Johnson, J.T., Myers, E., Herberman, R.B., et al. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res., 1993, 53, 5654-5662.
52. Whiteside, T.L., Chikamatsu, K., Nagashima, S., Okada, K. Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer. Anticancer Res., 1996, 16, 2357-2364.
53. Hayry, P., Totterman, T.H. Cytological and functional analysis of inflammatory infiltrates in human malignant tumors. I. Composition of the inflammatory infiltrates. Eur. J. Immunol., 1978, 8, 866-871.
54. Zoller, M., Goodman, M.L., Cummings, C.W. Guidelines for prognosis in head and neck cancer with nodal metastasis. Laryngoscope, 1978, 88, 135-140.
55. Itoh, K., Tilden, A.B., Balch, C.M. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res., 1986, 46, 3011-3017.
56. Hartveit, F. Breast cancer: poor short-term prognosis in cases with moderate lymphocyte infiltration at the tumour edge: a preliminary report. Oncol. Rep., 1998, 5, 423-426.
57. Marrogi, A.J., Munshi, A., Merogi, A.J., Ohadike, Y., El-Habashi, A., Marrogi, O.L., Freeman, S.M. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int. J. Cancer, 1997, 74, 492-501.
58. Bethwaite, P.B., Holloway, L.J., Thornton, A., Delahunt, B. Infiltration by immunocompetent cells in early stage invasive carcinoma of the uterine cervix: a prognostic study. Pathology, 1996, 28, 321-327.
59. Clemente, C.G., Mihm, M.C., Jr., Bufalino, R., Zurrida, S., Collini, P., Cascinelli, N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer, 1996, 77, 1303-1310.
60. Wada, Y., Nakashima, O., Kutami, R., Yamamoto, O., Kojiro, M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology, 1998, 27, 407-414.
61. Coca, S., Perez-Piqueras, J., Martinez, D., Colmenarejo, A., Saez, M.A., Vallejo, C., Martos, J.A., Moreno, M. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer, 1997, 79, 2320-2328.
62. Reichert, T.E., Strauss, L., Wagner, E.M., Gooding, W., Whiteside, T.L. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin. Cancer Res., 2002, 8, 3137-3145.
63. Kojima, M., Nakamura, S., Ichimura, K., Shimizu, K., Itoh, H., Masawa, N. Follicular lymphoma of the salivary gland: a clinicopathological and molecular study of six cases. Int. J. Surg. Pathol., 2001, 9, 287-293.
64. Yang, F.C., Agematsu, K., Nakazawa, T., Mori, T., Ito, S., Kobata, T., Morimoto, C., Komiyama, A. CD27/CD70 interaction directly induces natural killer cell killing activity. Immunology, 1996, 88, 289-293.
65. Yang, L., Yamagata, N., Yadav, R., Brandon, S., Courtney, R.L., Morrow, J.D., Shyr, Y., Boothby, M., Joyce, S., Carbone, D.P., Breyer, R.M. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J. Clin. Invest., 2003, 111, 727-735.
66. Thomas, G.R., Chen, Z., Leukinova, E., Van Waes, C., Wen, J. Cytokines IL-1 alpha, IL-6, and GM-CSF constitutively secreted by oral squamous carcinoma induce down-regulation of CD80 costimulatory molecule expression: restoration by interferon gamma. Cancer Immunol. Immunother., 2004, 53, 33-40.
67. Rhodus, N.L., Ho, V., Miller, C.S., Myers, S., Ondrey, F. NFkappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect. Prev., 2005, 29, 42-45.
68. Diehl, S., Rincon, M. The two faces of IL-6 on Th1/Th2 differentiation. Mol. Immunol., 2002, 39, 531-536.
69. Menetrier-Caux, C., Montmain, G., Dieu, M.C., Bain, C., Favrot, M.C., Caux, C., Blay, J.Y. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood, 1998, 92, 4778-4791.
70. Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., Carbone, D.P. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 1998, 92, 4150-4166.
71. Chang, C.C., Ciubotariu, R., Manavalan, J.S., Yuan, J., Colovai, A.I., Piazza, F., Lederman, S., Colonna, M., Cortesini, R., Dalla- Favera, R., Suciu-Foca, N. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat. Immunol., 2002, 3, 237-243.
72. Brooks, A.G., Posch, P.E., Scorzelli, C.J., Borrego, F., Coligan, J.E. NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor. J. Exp. Med., 1997, 185, 795-800.
73. D'Andrea, A., Chang, C., Franz-Bacon, K., McClanahan, T., Phillips, J.H., Lanier, L.L. Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes. J. Immunol., 1995, 155, 2306-2310.
74. Lazetic, S., Chang, C., Houchins, J.P., Lanier, L.L., Phillips, J.H. Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. J. Immunol., 1996, 157, 4741-4745.
75. Wagtmann, N., Rajagopalan, S., Winter, C.C., Peruzzi, M., Long, E.O. Killer cell inhibitory receptors specific for HLA-C and HLAB identified by direct binding and by functional transfer. Immunity, 1995, 3, 801-809.
76. Curiel, T.J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K.L., Daniel, B., Zimmermann, M.C., David, O., Burow, M., Gordon, A., Dhurandhar, N., Myers, L., Berggren, R., Hemminki, A., Alvarez, R.D., Emilie, D., Curiel, D.T., Chen, L., Zou, W. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med., 2003, 9, 562-567.
77. Greten, T.F., Manns, M.P., Korangy, F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol, 2011, 802-806.
78. Vuk-Pavlovic, S. Rebuilding immunity in cancer patients. Blood Cells Mol. Dis., 2008, 40, 94-100.
79. Coffelt, S.B., Hughes, R., Lewis, C.E. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim. Biophys. Acta, 2009, 1796, 11-18.
80. Mantovani, A., Sica, A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol., 2010, 22, 231-237.
81. Yaguchi, T., Sumimoto, H., Kudo-Saito, C., Tsukamoto, N., Ueda, R., Iwata-Kajihara, T., Nishio, H., Kawamura, N., Kawakami, Y.The mechanisms of cancer immunoescape and development of overcoming strategies. Int. J. Hematol., 2011, 93, 294-300.
82. Jewett, A., Arasteh, A., Tseng, H.C., Behel, A., Arasteh, H., Yang, W., Cacalano, N.A., Paranjpe, A. Strategies to rescue mesenchymal stem cells (MSCs) and dental pulp stem cells (DPSCs) from NK cell mediated cytotoxicity. PLoS ONE, 2010, 5, e9874.
83. Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., Dalton, W., Jove, R., Pardoll, D., Yu, H. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med., 2004, 10, 48-54.
84. Abdulkarim, B., Sabri, S., Deutsch, E., Chagraoui, H., Maggiorella, L., Thierry, J., Eschwege, F., Vainchenker, W., Chouaib, S., Bourhis, J. Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene, 2002, 21, 2334-2346.
85. Murakami, J., Asaumi, J., Kawai, N., Tsujigiwa, H., Yanagi, Y., Nagatsuka, H., Inoue, T., Kokeguchi, S., Kawasaki, S., Kuroda, M., Tanaka, N., Matsubara, N., Kishi, K. Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer. Cancer Chemother. Pharmacol., 2005, 56, 22-28.
86. Murakami, J., Asaumi, J., Maki, Y., Tsujigiwa, H., Nagatsuka, H., Kokeguchi, S., Inoue, T., Kawasaki, S., Tanaka, N., MacPhee, D., Matsubara, N., Kishi, K. Influence of CpG island methylation status in O6-methylguanine-DNA methyltransferase expression of oral cancer cell lines. Oncol. Rep., 2004, 12, 339-345.
87. Berlin, A.L., Paller, A.S., Chan, L.S. Incontinentia pigmenti: a review and update on the molecular basis of pathophysiology. J. Am. Acad. Dermatol., 2002, 47, 169-187; quiz 188-190.
88. Greten, F.R., Eckmann, L., Greten, T.F., Park, J.M., Li, Z.W., Egan, L.J., Kagnoff, M.F., Karin, M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 2004, 118, 285-296.
89. Greten, F.R., Karin, M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett., 2004, 206, 193-199.
90. Seitz, C.S., Lin, Q., Deng, H., Khavari, P.A. Alterations in NFkappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc. Natl. Acad. Sci. USA, 1998, 95, 2307-2312.
91. van Hogerlinden, M., Rozell, B.L., Ahrlund-Richter, L., Toftgard, R. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res., 1999, 59, 3299-3303.
92. van Hogerlinden, M., Rozell, B.L., Toftgard, R., Sundberg, J.P. Characterization of the progressive skin disease and inflammatory cell infiltrate in mice with inhibited NF-kappaB signaling. J. Invest. Dermatol., 2004, 123, 101-108.
93. Inagaki, A., Soeda, A., Oka, N., Kitajima, H., Nakagawa, J., Motohashi, T., Kunisada, T., Iwama, T. Long-term maintenance of brain tumor stem cell properties under at non-adherent and adherent culture conditions. Biochem. Biophys. Res. Commun., 2007, 361, 586-592.
94. Oka, N., Soeda, A., Inagaki, A., Onodera, M., Maruyama, H., Hara, A., Kunisada, T., Mori, H., Iwama, T. VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem. Biophys. Res. Commun., 2007, 360, 553-559.
95. Soeda, A., Inagaki, A., Oka, N., Ikegame, Y., Aoki, H., Yoshimura, S., Nakashima, S., Kunisada, T., Iwama, T. Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. J. Biol. Chem., 2008, 283, 10958-10966.
96. Rahaman, S.O., Harbor, P.C., Chernova, O., Barnett, G.H., Vogelbaum, M.A., Haque, S.J. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene, 2002, 21, 8404-8413.
97. Jewett, A., Bonavida, B. Target-induced anergy of natural killer cytotoxic function is restricted to the NK-target conjugate subset. Cell Immunol., 1995, 160, 91-97.
98. Hu, P.F., Hultin, L.E., Hultin, P., Hausner, M.A., Hirji, K., Jewett, A., Bonavida, B., Detels, R., Giorgi, J.V. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 1995, 10, 331-340.
99. Kuss, I., Saito, T., Johnson, J.T., Whiteside, T.L. Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin. Cancer Res., 1999, 5, 329-334.
100. Lai, P., Rabinowich, H., Crowley-Nowick, P.A., Bell, M.C., Mantovani, G., Whiteside, T.L. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin. Cancer Res., 1996, 2, 161-173.
101. Patankar, M.S., Yu, J., Morrison, J.C., Belisle, J.A., Lattanzio, F.A., Deng, Y., Wong, N.K., Morris, H.R., Dell, A., Clark, G.F. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol., 2005, 99, 704-713.
102. Mandelboim, O., Malik, P., Davis, D.M., Jo, C.H., Boyson, J.E., Strominger, J.L. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc. Natl. Acad. Sci. USA, 1999, 96, 5640-5644.
103. Azzoni, L., Anegon, I., Calabretta, B., Perussia, B. Ligand binding to Fc gamma R induces c-myc-dependent apoptosis in IL-2- stimulated NK cells. J. Immunol., 1995, 154, 491-499.
104. Ortaldo, J.R., Mason, A.T., O'Shea, J.J. Receptor-induced death in human natural killer cells: involvement of CD16. J. Exp. Med., 1995, 181, 339-344.
105. Bonavida, B., Braquet, M., Lebow, L.T., Jewett, A. Qualitative and quantitative analysis of subpopulations of cytotoxic effector cells by flow cytometry. J. Lipid Mediat. Cell Signal., 1994, 9, 19-25.
106. Bonavida, B., Lebow, L.T., Jewett, A. Natural killer cell subsets: maturation, differentiation and regulation. Nat. Immun., 1993, 12, 194-208.
107. Jewett, A., Bonavida, B. Activation of the human immature natural killer cell subset by IL-12 and its regulation by endogenous TNFalpha and IFN-gamma secretion. Cell Immunol., 1994, 154, 273-286.
108. Jewett, A., Bonavida, B. Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells. J. Clin. Immunol., 1995, 15, 35-44.
109. Jewett, A., Bonavida, B. MHC-Class I antigens regulate both the function and the survival of human peripheral blood NK cells: role of endogenously secreted TNF-alpha. Clin. Immunol., 2000, 96, 19-28.
110. Jewett, A., Cacalano, N.A., Head, C., Teruel, A. Coengagement of CD16 and CD94 receptors mediates secretion of chemokines and induces apoptotic death of naive natural killer cells. Clin. Cancer Res., 2006, 12, 1994-2003.
111. Jewett, A., Teruel, A., Romero, M., Head, C., Cacalano, N. Rapid and potent induction of cell death and loss of NK cell cytotoxicity against oral tumors by F(ab')2 fragment of anti-CD16 antibody. Cancer Immunol. Immunother., 2008, 57, 1053-1066.
112. Romero-Reyes, M., Head, C., Cacalano, N.A., Jewett, A. Potent induction of TNF-alpha during interaction of immune effectors with oral tumors as a potential mechanism for the loss of NK cell viability and function. Apoptosis, 2007, 12 (11), 2063-2075.
113. Cooper, M.A., Fehniger, T.A., Caligiuri, M.A. The biology of human natural killer-cell subsets. Trends Immunol., 2001, 22, 633-640.
114. Nemeth, E., Baird, A.W., O'Farrelly, C. Microanatomy of the liver immune system. Semin. Immunopathol., 2009, 31, 333-343.